Personalized ctDNA micro-panels can monitor and predict clinical outcomes for patients with triple-negative breast cancer

Circulating tumor DNA (ctDNA) in peripheral blood has been used to predict prognosis and therapeutic response for triple-negative breast cancer (TNBC) patients. However, previous approaches typically use large comprehensive panels of genes commonly mutated across all breast cancers. Given the reduct...

Descripción completa

Detalles Bibliográficos
Autores principales: Barnell, Erica K., Fisk, Bryan, Skidmore, Zachary L., Cotto, Kelsy C., Basu, Anamika, Anand, Aparna, Richters, Megan M., Luo, Jingqin, Fronick, Catrina, Anurag, Meenakshi, Fulton, Robert, Ellis, Matthew J., Griffith, Obi L., Griffith, Malachi, Ademuyiwa, Foluso O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9588015/
https://www.ncbi.nlm.nih.gov/pubmed/36273232
http://dx.doi.org/10.1038/s41598-022-20928-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9588015/
https://www.ncbi.nlm.nih.gov/pubmed/36273232
http://dx.doi.org/10.1038/s41598-022-20928-8

Ejemplares similares